D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $5.00 target price on the stock.

Separately, StockNews.com started coverage on VolitionRx in a research report on Friday, March 28th. They issued a “sell” rating on the stock.

VolitionRx Trading Down 9.0 %

VNRX opened at $0.52 on Monday. The firm’s fifty day simple moving average is $0.58 and its 200 day simple moving average is $0.63. The stock has a market capitalization of $48.06 million, a P/E ratio of -1.44 and a beta of 1.09. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.02.

Insider Activity

In other news, CEO Cameron John Reynolds bought 181,818 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average cost of $0.55 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of VolitionRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in VNRX. Lagoda Investment Management L.P. grew its position in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Geode Capital Management LLC grew its holdings in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the period. Millennium Management LLC acquired a new position in VolitionRx during the fourth quarter worth approximately $36,000. Two Sigma Securities LLC bought a new stake in VolitionRx in the fourth quarter valued at approximately $29,000. Finally, Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares during the last quarter. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.